{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:04:16Z","timestamp":1740146656943,"version":"3.37.3"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234811","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T17:42:40Z","timestamp":1592329360000},"page":"e0234811","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-existing minor variants with NS5A L31M\/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection"],"prefix":"10.1371","volume":"15","author":[{"given":"Naoki","family":"Morishita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-607X","authenticated-orcid":true,"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaharu","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"pone.0234811.ref001","unstructured":"World Health Organization. hepatitis C. 2019 (9 July). Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed on April 14, 2020."},{"issue":"4","key":"pone.0234811.ref002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"pone.0234811.ref003","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","article-title":"Distribution of hepatitis C virus genotypes in a diverse US integrated health care population","volume":"84","author":"MM Manos","year":"2012","journal-title":"J Med Virol"},{"issue":"1 Suppl","key":"pone.0234811.ref004","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0234811.ref005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"AS Lok","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0234811.ref006","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"9954","key":"pone.0234811.ref007","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"M Manns","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"pone.0234811.ref008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Y Suzuki","year":"2013","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0234811.ref009","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"S Yoshimi","year":"2015","journal-title":"J Med Virol"},{"issue":"4","key":"pone.0234811.ref010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"et al. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals","volume":"154","author":"J Dietz","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"pone.0234811.ref011","first-page":"1439","article-title":"Analysis of Hepatitis C Virus NS5A Region in Patients with Cirrhosis Using an Deep Pyrosequencing Method","volume":"63","author":"F Keskin","year":"2017","journal-title":"Clin Lab"},{"key":"pone.0234811.ref012","doi-asserted-by":"crossref","first-page":"41660","DOI":"10.1038\/srep41660","article-title":"Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment","volume":"7","author":"Y Kai","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0234811.ref013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/hepr.12994","article-title":"Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b","volume":"48","author":"K Honda","year":"2018","journal-title":"Hepatol Res"},{"key":"pone.0234811.ref014","first-page":"720","article-title":"Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using PCR-Invader assay","volume":"55","author":"K Tadokoro","year":"2014","journal-title":"Kanzo (in Japanese)"},{"issue":"1\u20132","key":"pone.0234811.ref015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mrfmmm.2004.08.016","article-title":"The Invader assay for SNP genotyping","volume":"573","author":"M Olivier","year":"2005","journal-title":"Mutat Res"},{"issue":"7","key":"pone.0234811.ref016","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/90290","article-title":"An invasive cleavage assay for direct quantitation of specific RNAs","volume":"19","author":"PS Eis","year":"2001","journal-title":"Nat Biotechnol"},{"issue":"6","key":"pone.0234811.ref017","doi-asserted-by":"crossref","first-page":"e0130022","DOI":"10.1371\/journal.pone.0130022","article-title":"Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay","volume":"10","author":"S Yoshimi","year":"2015","journal-title":"PLoS One"},{"key":"pone.0234811.ref018","first-page":"113","article-title":"Correlation between efficacy of daclatasvir\/asunaprevir combination therapy and HCV NS3\/NS5A resistance-associated variants detected by the PCR-Invader assay","volume":"56","author":"Y Karino","year":"2015","journal-title":"Kanzo (in Japanese)"},{"issue":"11","key":"pone.0234811.ref019","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00535-015-1108-6","article-title":"Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice","volume":"50","author":"Y Kai","year":"2015","journal-title":"J Gastroenterol"},{"issue":"1","key":"pone.0234811.ref020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3851\/IMP2976","article-title":"Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection","volume":"21","author":"H Kinugasa","year":"2016","journal-title":"Antivir Ther"},{"issue":"2","key":"pone.0234811.ref021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","article-title":"APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?","volume":"13","author":"T Kanda","year":"2019","journal-title":"Hepatol Int"},{"issue":"3","key":"pone.0234811.ref022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3350\/cmh.2018.1004","article-title":"2017 KASL Clinical Practice Guidelines for Management of Hepatitis C: Treatment of Chronic Hepatitis C","volume":"24","author":"Korean Association for the Study of the Liver (KASL)","year":"2018","journal-title":"Clin Mol Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T17:43:14Z","timestamp":1592329394000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234811"}},"subtitle":[],"editor":[{"given":"Jason","family":"Blackard","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234811","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,6,16]]}}}